Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury

Background Heme is an essential iron-containing molecule for cardiovascular physiology, but in excess it may increase oxidative stress. Failing human hearts have increased heme levels, with upregulation of the rate-limiting enzyme in heme synthesis, δ-aminolevulinic acid synthase 2 (ALAS2), which is normally not expressed in cardiomyocytes. We hypothesized that increased heme accumulation (through cardiac overexpression of ALAS2) leads to increased oxidative stress and cell death in the heart. Methods and Results We first showed that ALAS2 and heme levels are increased in the hearts of mice subjected to coronary ligation. To determine the causative role of increased heme in the development of heart failure, we generated transgenic mice with cardiac-specific overexpression of ALAS2. While ALAS2 transgenic mice have normal cardiac function at baseline, their hearts display increased heme content, higher oxidative stress, exacerbated cell death, and worsened cardiac function after coronary ligation compared to nontransgenic littermates. We confirmed in cultured cardiomyoblasts that the increased oxidative stress and cell death observed with ALAS2 overexpression is mediated by increased heme accumulation. Furthermore, knockdown of ALAS2 in cultured cardiomyoblasts exposed to hypoxia reversed the increases in heme content and cell death. Administration of the mitochondrial antioxidant MitoTempo to ALAS2-overexpressing cardiomyoblasts normalized the elevated oxidative stress and cell death levels to baseline, indicating that the effects of increased ALAS2 and heme are through elevated mitochondrial oxidative stress. The clinical relevance of these findings was supported by the finding of increased ALAS2 induction and heme accumulation in failing human hearts from patients with ischemic cardiomyopathy compared to nonischemic cardiomyopathy. Conclusions Heme accumulation is detrimental to cardiac function under ischemic conditions, and reducing heme in the heart may be a novel approach for protection against the development of heart failure.

[1]  Y. Lopatin Metabolic Therapy in Heart Failure. , 2015, Cardiac failure review.

[2]  H. Ardehali,et al.  Role of Heme in Cardiovascular Physiology and Disease , 2015, Journal of the American Heart Association.

[3]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[4]  M. Gheorghiade,et al.  Molecular and Cellular Basis of Viable Dysfunctional Myocardium , 2014, Circulation. Heart failure.

[5]  Steven P Jones,et al.  Metabolomic Analysis of Pressure-Overloaded and Infarcted Mouse Hearts , 2014, Circulation. Heart failure.

[6]  T. Poulos Heme enzyme structure and function. , 2014, Chemical reviews.

[7]  R. Mutharasan,et al.  Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. , 2014, The Journal of clinical investigation.

[8]  Arineh Khechaduri,et al.  Heme levels are increased in human failing hearts. , 2013, Journal of the American College of Cardiology.

[9]  M. Gheorghiade,et al.  Mitochondria as a therapeutic target in heart failure. , 2013, Journal of the American College of Cardiology.

[10]  M. Laakso,et al.  Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production , 2012, EMBO molecular medicine.

[11]  R. Mutharasan,et al.  Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export , 2012, Proceedings of the National Academy of Sciences.

[12]  Michael A. Burke,et al.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies , 2012, European journal of heart failure.

[13]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[14]  R. Payne,et al.  The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications. , 2011, Progress in pediatric cardiology.

[15]  Anwara . Khan,et al.  Control of intracellular heme levels: heme transporters and heme oxygenases. , 2011, Biochimica et biophysica acta.

[16]  R. Bolli,et al.  Cardioprotective and Antiapoptotic Effects of Heme Oxygenase-1 in the Failing Heart , 2010, Circulation.

[17]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[18]  M. Tsironi,et al.  Assessment and Treatment of Cardiac Iron Overload in Thalassemia , 2009, Hemoglobin.

[19]  J. Barton,et al.  Multi-Organ Iron Overload in an African-American Man with ALAS2 R452S and SLC40A1 R561G , 2008, Acta Haematologica.

[20]  L. Wojnar,et al.  Detection of mitochondrial dysfunction by EPR technique in mouse model of dilated cardiomyopathy. , 2008, Free radical biology & medicine.

[21]  Y. Kohgo,et al.  Body iron metabolism and pathophysiology of iron overload , 2008, International journal of hematology.

[22]  J. Abkowitz,et al.  A Heme Export Protein Is Required for Red Blood Cell Differentiation and Iron Homeostasis , 2008, Science.

[23]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2008, Journal of the American College of Cardiology.

[24]  P. Duarte,et al.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.

[25]  Kiriko Kaneko,et al.  Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. , 2007, The Tohoku journal of experimental medicine.

[26]  L. Opie,et al.  Metabolic mechanisms in heart failure. , 2007, Circulation.

[27]  L. Papadopoulou,et al.  Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. , 2006, Pharmacology & therapeutics.

[28]  Li Zhang,et al.  Heme: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases , 2006, Cell Research.

[29]  Sanjay Kumar,et al.  Free heme toxicity and its detoxification systems in human. , 2005, Toxicology letters.

[30]  Albert Hofman,et al.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.

[31]  N. Wijayanti,et al.  Biology of heme in health and disease. , 2004, Current medicinal chemistry.

[32]  S. Laradi,et al.  Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[33]  G. Francis,et al.  Heart failure therapy at a crossroad: are there limits to the neurohormonal model? , 2003, Journal of the American College of Cardiology.

[34]  P. Aisen,et al.  Chemistry and biology of eukaryotic iron metabolism. , 2001, The international journal of biochemistry & cell biology.

[35]  J. Alam,et al.  Hmox-1 Constitutes an Adaptive Response to Effect Antioxidant Cardioprotection: A Study With Transgenic Mice Heterozygous for Targeted Disruption of the Heme Oxygenase-1 Gene , 2001, Circulation.

[36]  P. Sarathchandra,et al.  Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. , 2000, American journal of physiology. Heart and circulatory physiology.

[37]  S. Ryter,et al.  The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. , 2000, Free radical biology & medicine.

[38]  T. Sadlon,et al.  Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. , 1999, The international journal of biochemistry & cell biology.

[39]  D. Bagchi,et al.  Oxidative mechanisms in the toxicity of metal ions. , 1995, Free radical biology & medicine.

[40]  J. Kushner,et al.  Heme regulation of HeLa cell transferrin receptor number. , 1984, The Journal of biological chemistry.

[41]  F. Takaku,et al.  Aminolevulinic acid synthetase activity in erythroblasts of patients with primary sideroblastic anemia. , 1973, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[42]  E. Beutler,et al.  Severe iron overload with a novel aminolevulinate synthase mutation and hepatitis C infection. A case report. , 2009, Blood cells, molecules & diseases.

[43]  A. Koeppen,et al.  Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia , 2008, The Cerebellum.

[44]  M. Gassmann,et al.  Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. , 2003, Blood.

[45]  P. Ponka Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. , 1997, Blood.

[46]  R. Meneghini Iron homeostasis, oxidative stress, and DNA damage. , 1997, Free radical biology & medicine.

[47]  F. Takaku,et al.  -Aminolevulinic acid synthetase activity of human bone marrow erythroid cells in various hematological disorders. , 1972, The Tohoku journal of experimental medicine.

[48]  W. Tourtellotte,et al.  JCB: ARTICLE Transcriptional regulation of myotube fate specification and intrafusal muscle fiber morphogenesis , 2022 .